This page holds a finished NU 636 Unit 1 drug class profile turning each pharmacokinetic property into a dosing, selection or monitoring consequence rather than reporting it. Searches like "nu 636 unit 1 assignment example", "nu636 unit 1 sample" and "nu 636 unit 1 example" land here.
The NU 636 Unit 1 drug class profile, in full
Drug Class Profile: Direct Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation
Student Name
Department of Nursing, Herzing University
NU 636: Advanced Pharmacology
Instructor Name
January 21, 2026
Drug Class Profile: Direct Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation
The Class and the Problem It Solves
Direct oral anticoagulants (DOACs) are oral drugs that inhibit a single clotting factor directly: dabigatran inhibits thrombin (factor IIa), while apixaban, rivaroxaban, and edoxaban inhibit factor Xa. In primary care they are most often prescribed to prevent stroke in nonvalvular atrial fibrillation, where stasis in the left atrial appendage allows thrombus to form and embolize. Before this class, warfarin was the standard oral option, and its narrow therapeutic range, food and drug interactions, and need for regular INR monitoring shaped every prescribing decision. This profile treats each property of the DOACs as a decision it creates for the prescriber.
Mechanism at the Target, and the Effects It Predicts
Factor Xa sits at the convergence of the intrinsic and extrinsic pathways and converts prothrombin to thrombin; thrombin then converts fibrinogen to fibrin and amplifies its own generation by activating factors V, VIII, and XI. Inhibiting factor Xa reduces the burst of thrombin generation; inhibiting thrombin directly blocks the final step. Both approaches reduce clot formation in the low-flow environment of the fibrillating atrium (Rosenthal & Burchum, 2021).
The intended effect and the principal adverse effect come from the same mechanism: reduced thrombin generation prevents pathological clots and also impairs hemostatic ones, so bleeding is the predictable harm. Because the drugs act on one factor rather than on several vitamin K-dependent factors as warfarin does, their effect is more predictable, but the bleeding risk remains. When apixaban was tested head to head against warfarin, the apixaban group had fewer strokes and embolic events and less major bleeding, including less intracranial hemorrhage (Granger et al., 2011). Dabigatran has a second, class-member-specific effect: its capsule contains tartaric acid to aid absorption, which accounts for the dyspepsia that is its most common reason for discontinuation.
Pharmacokinetics, Each With Its Consequence
Absorption and onset. All four agents reach peak effect within about one to four hours. Consequence: no bridging with a parenteral anticoagulant is needed when starting, unlike warfarin, and a missed dose leaves the patient unprotected within a day. Rivaroxaban at the 15 mg and 20 mg doses must be taken with the evening meal, because food substantially increases its absorption; a patient who takes it on an empty stomach receives a lower effective dose. Dabigatran capsules must not be opened, because the pellets alone produce much higher absorption and bleeding risk.
Half-life. Half-lives are roughly 12 hours for apixaban, 12 to 17 hours for dabigatran, 10 to 14 hours for edoxaban, and 5 to 9 hours for rivaroxaban in younger adults, longer in older adults (Steffel et al., 2021). Consequence: apixaban and dabigatran are dosed twice daily, and adherence to both doses matters because protection falls with each missed dose. The short duration also means the drugs can usually be held for one to three days before most procedures, depending on kidney function and bleeding risk, without bridging.
Elimination. This is the property that most separates class members. About 80% of dabigatran is cleared by the kidneys, roughly half of edoxaban, about a third of rivaroxaban as unchanged drug, and about 27% of apixaban (Steffel et al., 2021). Consequence: declining kidney function raises dabigatran levels more than any other member, which makes apixaban the member least affected by renal impairment and dabigatran the one to avoid when creatinine clearance is falling or unstable. Doses of each agent must be checked against creatinine clearance estimated with the Cockcroft-Gault formula, because that estimate, not eGFR, is what the dosing trials used.
Choosing Between Members
The properties above, not preference, decide selection. Apixaban suits older adults and those with reduced or fluctuating kidney function because of its lower renal clearance and favorable bleeding profile, at the cost of twice-daily dosing. Rivaroxaban and edoxaban suit patients for whom once-daily dosing is the best route to adherence, provided kidney function is adequate and, for rivaroxaban, that it can be taken with food. Dabigatran suits patients with good and stable kidney function, and it is the only member with a specific reversal agent, idarucizumab, that has been widely available for years; andexanet alfa reverses factor Xa inhibitors. Cost and coverage often decide between otherwise equivalent choices, and the prescriber should check the patient's plan before choosing rather than after.
Interactions by Pathway
All four agents are substrates of P-glycoprotein, and apixaban and rivaroxaban are also substantially metabolized by cytochrome P450 3A4. Strong inducers of both pathways, such as rifampin, carbamazepine, phenytoin, and St. John's wort, lower DOAC levels and should generally be avoided, because the patient loses stroke protection. Strong inhibitors of both pathways raise levels and bleeding risk. Pharmacodynamic interactions matter as much: aspirin, other antiplatelet agents, nonsteroidal anti-inflammatory drugs, and selective serotonin reuptake inhibitors add bleeding risk through separate mechanisms, and the reason for any combination should be reviewed at every visit (Steffel et al., 2021).
Monitoring With Intervals and Thresholds
Routine coagulation monitoring is not required, but the drugs are not monitoring free. Before starting: complete blood count, creatinine with calculated creatinine clearance, and liver function. During treatment: kidney function and blood count at least yearly, and more often when kidney function is reduced; a practical rule is to check kidney function every few months, with the interval in months roughly equal to creatinine clearance divided by 10 when clearance is below 60 mL/min (Steffel et al., 2021). Any drop in hemoglobin of 2 g/dL or more, or a fall in creatinine clearance below the threshold for the current dose, prompts a dose review. Each visit should also confirm adherence, bleeding events, and new interacting medications.
The Patient for Whom This Class Is the Wrong Answer
DOACs should not be used in patients with mechanical heart valves. In the trial of dabigatran in patients with mechanical valves, thromboembolic and bleeding events were both higher than with warfarin, and the trial was stopped early (Eikelboom et al., 2013). They are also not appropriate for moderate to severe mitral stenosis, for patients with antiphospholipid syndrome who test positive for all three antibodies, or for patients on unavoidable strong interacting drugs such as rifampin. For a patient with end-stage kidney disease, the evidence is limited, and the choice requires specialist input. In each case, warfarin remains the better-supported option, and the reasoning is the same: the population in which the class was tested did not include these patients, or included them and showed harm.
References
Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., Harper, R., Khder, Y., Lobmeyer, M. T., Maas, H., Voigt, J.-U., Simoons, M. L., & Van de Werf, F. (2013). Dabigatran versus warfarin in patients with mechanical heart valves. New England Journal of Medicine, 369(13), 1206-1214. https://doi.org/10.1056/NEJMoa1300615
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., Bahit, M. C., Diaz, R., Easton, J. D., Ezekowitz, J. A., Flaker, G., Garcia, D., Geraldes, M., Gersh, B. J., Golitsyn, S., ... Wallentin, L. (2011). Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 365(11), 981-992. https://doi.org/10.1056/NEJMoa1107039
Rosenthal, L. D., & Burchum, J. R. (2021). Lehne's pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.). Elsevier.
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., Sinnaeve, P., Vanassche, T., Potpara, T., Camm, A. J., & Heidbuchel, H. (2021). 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace, 23(10), 1612-1676. https://doi.org/10.1093/europace/euab065
What a finished NU 636 Unit 1 drug class profile looks like
The finished profile looks nothing like a reference card. Absorption, distribution, metabolism and excretion each appear with a consequence attached, so a hepatic clearance route is followed immediately by what it means when liver function drops. The receptor mechanism is stated in enough detail to explain both the intended effect and the predictable adverse ones, which is what allows the profile to argue rather than list. Members of the class are separated by the properties that would make a prescriber pick one over another, not by an alphabetical roll. Interactions are named at the enzyme or transporter rather than as a warning to check. Monitoring appears with intervals and thresholds, and the closing section describes the patient for whom this class is the wrong answer.
How a NU 636 Unit 1 example is structured
The example opens with the class and the clinical problem it exists to solve, in three or four lines, so the reader knows what is being profiled and why. The second section handles the mechanism at the receptor, and it is written to be used later, since the adverse effect section will be derived from it rather than listed separately. The third section runs the pharmacokinetic properties, and each one is followed by its consequence in the same sentence or the next, which is the structural habit that separates this deliverable from a summary. The fourth section compares members inside the class on the properties that actually decide selection. The fifth names interactions by pathway. The sixth sets out monitoring with intervals attached. The profile closes on exclusion, describing the patient this class should not receive and the reasoning behind that boundary.
Each property converted to a consequence
A half-life is followed by the dosing interval it implies, and a clearance route by the organ whose failure would change the dose.
Adverse effects derived from mechanism
Predictable effects are traced back to the receptor action that causes them, which turns a warning list into an argument a grader can credit.
Members separated by what decides selection
The profile compares agents inside the class on the properties a prescriber would weigh, rather than presenting them as interchangeable options.
Interactions named at the pathway
The enzyme or transporter involved is stated, along with the direction of the effect, so the interaction has a mechanism instead of a caution.
Monitoring with intervals attached
Every parameter carries a timeframe and a threshold, since an instruction to monitor renal function without either cannot be followed by anyone.
The patient this class is wrong for
A closing section describes who should not receive the class and why, which shows the profile reasoning rather than reciting product information.
Where marks go in NU 636 Unit 1
The commonest loss in this deliverable is the package insert rewritten. Accurate content copied from labeling, with no consequence drawn from any of it, satisfies nothing, because the criterion is asking what the property means for a decision. Kinetics reported as numbers is the same failure in another form: a stated half-life earns nothing until the interval follows from it. Adverse effects listed without frequency, severity or a mechanism read as a warning label. Monitoring written as a category, with no interval and no action threshold, leaves the safety criterion unfilled. Profiles that treat every member of the class as equivalent skip the comparison the course is built on. Sources drawn from consumer drug pages rather than current references cost their own line.
Get a NU 636 Unit 1 example written to your instructions
Send the Unit 1 instructions and the rubric from your NU 636 classroom, plus the class you were assigned or intend to profile. We write a custom example against those criteria, with each property carried through to a dosing or monitoring consequence, and return it in 24 to 48 hours. The first custom sample is free.
NU 636 Unit 1 questions, answered
How is a class profile different from a drug card?
A card stores facts for recall. A profile argues from those facts toward decisions, which is why the graduate version reads so differently. Every line that would sit in a card as data appears here with a consequence beside it, and the sections that carry the most credit, comparison inside the class and the exclusion criteria at the end, do not exist on a card at all.
How specific does the monitoring section have to be?
Specific enough that someone could follow it without asking a question. That means the parameter, the baseline before starting, the interval afterward, the threshold that triggers action and what the action is. An instruction to check potassium periodically is the version that loses marks, because periodically is not an interval and checking is not an action.
Which sources are acceptable in this course?
Current pharmacology references, peer-reviewed literature and recognized clinical guidance carry the load in most sections. Consumer medication pages and commercial summaries are the ones to keep out of load-bearing positions. Currency matters more here than in most graduate work, since dosing and safety guidance is revised, so check whether your instructions set a publication window before you build the reference list.